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Targeting human prostate cancer with
111In-labeled D2B IgG, F(ab′)2 and Fab
fragments in nude mice with PSMA-
expressing xenografts
Susanne Lütjea*, CatharinaM. van Rija, GerbenM. Franssena, Giulio Fracassob,
Wijnand Helfrichc, Annemarie Eeka, Wim J. Oyena, Marco Colombattib
and Otto C. Boermana
D2B is a new monoclonal antibody directed against an extracellular domain of prostate-speciﬁc membrane antigen
(PSMA), which is overexpressed in prostate cancer. The potential of D2B IgG, and F(ab′)2 and Fab fragments of this
antibody for targeting prostate cancer was determined in mice bearing subcutaneous prostate cancer xenografts. The
optimal time point for imaging was determined in biodistribution and microSPECT imaging studies with 111In-D2B IgG,
111In-capromab pendetide, 111In-D2B F(ab′)2 and
111In-D2B Fab fragments in mice with PSMA-expressing LNCaP and
PSMA-negative PC3 tumors at several time points after injection. All 111In-labeled antibody formats speciﬁcally accu-
mulated in the LNCaP tumors, with highest uptake of 111In-D2B IgG and 111In-capromab pendetide at 168h p.i.
(94.8±19.2% injected dose per gram (ID/g) and 16.7±2.2% ID/g, respectively), whereas uptake of 111In-D2B F(ab′)2 and
111In-D2B Fab fragments peaked at 24h p.i. (12.1±3.0% ID/g and 15.1±2.9% ID/g, respectively). Maximum LNCaP
tumor-to-blood ratios were 13.0±2.3 (168h p.i.), 6.2±0.7 (24h p.i.), 23.0±4.0 (24h p.i.) and 4.5±0.6 (168h p.i.) for
111In-D2B IgG, 111In-F(ab′)2,
111In-Fab and 111In-capromab pendetide, respectively. LNCaP tumors were clearly visualized
with microSPECT with all antibody formats. This study demonstrates the feasibility of D2B IgG, F(ab′)2 and Fab fragments
for targeting PSMA-expressing prostate cancer xenografts. Copyright © 2014 John Wiley & Sons, Ltd.
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1. INTRODUCTION
Prostate cancer is the second leading cause of cancer-related
deaths in men in the Western world, and since metastatic prostate
cancer is incurable, early diagnosis represents the most effective
strategy with a change towards curative treatment options. Addi-
tionally, differentiation between malignant and nonmalignant
prostate tissue is essential for the initiation of adequate treatment
and the evaluation of response to therapy and relapse.
At present, prostate cancer is usually diagnosed by a combina-
tion of digital rectal examination, evaluation of prostate-speciﬁc
antigen serum concentrations and transrectal ultrasound (TRUS)-
guided biopsy (1). However, the ability of TRUS to delineate small
cancer foci and differentiate between benign prostatic hyperplasia,
atrophy, inﬂammatory processes and malignancies is limited.
Magnetic resonance imaging (MRI) can be used for primary diag-
nostic purposes of prostate cancer, for instance if clinical suspicion
for prostate cancer persists despite negative prostate biopsies, or
for local tumor staging purposes (1). Positron emission tomogra-
phy (PET) imaging is a useful imaging modality to detect meta-
static disease in several cancers (2). However, 18F-FDG-PET is not
suited for staging patients with prostate cancer, owing to the rela-
tively low avidity of prostate cancer for 18F-FDG (3). The most
commonly used approach to identify bone metastases in prostate
cancer patients are bone scans. In equivocal cases, 11C-choline- or
18F-ﬂuoride-PET/CT can be an option (1). Recent developments in
molecular imaging include radiolabeled monoclonal antibodies
(mAb) used as tracers for single-photon emission tomography
(SPECT) and PET.
The prostate-speciﬁc membrane antigen (PSMA) is a type II
membrane glycoprotein (4) that provides an excellent target
for prostate cancer imaging owing to its selective overexpression
on the surface of prostate cancer cells (5). Initial validation of PSMA
as an in vivo target resulted from imaging with the 111In-labeled
mAb capromab pendetide (7E11/CYT-356, Prostascint®) (6), which
is approved by the US Food and Drug Administration for diagnos-
tic imaging in patients with biopsy-proven prostate cancer, who
are at high risk for pelvic lymph node metastases (7). However,
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capromab pendetide is directed against an epitope on an intra-
cellular domain of PSMA (8). Therefore, binding of this antibody
to tumor cells requires uptake of the antibody into the cells. It
has been postulated that capromab pendetide may only bind to
dying or necrotic cells with cellular membranes that are permeable
for IgG. The mAb J591, which is directed against an extracellular
epitope of PSMA, has shown great potential for diagnostic radio-
nuclide imaging in prostate cancer patients (9–11), especially
when labeled with 111In, showing excellent tumor targeting of
metastases (12).
In the present study, we use a new mAb D2B IgG, a murine
IgG1 mAb directed against an epitope on the extracellular
domain of PSMA (13). We characterized the tumor targeting
capacity of D2B IgG and compared it with those of F(ab′)2 and
Fab fragments of D2B IgG to evaluate possible limitations such
as low tumor-to-blood ratios that can occur owing to relatively
slow clearance of intact antibodies compared to fragments (14).
In these experiments, capromab pendetide was used as a
reference.
2. MATERIALS AND METHODS
2.1. Production and puriﬁcation of antibodies and fragments
Themonoclonal antibody D2B (IgG1) was puriﬁed from hybridoma
culture supernatant by Protein A afﬁnity chromatography. The
antibody secreting cells were obtained according to the hybridoma
technology from mice that were immunized with a cell lysate of
membranes of LNCaP cells. Mice were injected three times (days 0,
14 and 28) i.p. with 800μg of lysate and Freund’s adjuvant (Sigma-
Aldrich, St Louis, MO, USA). On the last three days before the spleen
of the mice was harvested, mice were boosted with 10μg of
recombinant PSMA protein (Novagen, Milan, Italy) intravenously.
F(ab′)2 fragments were produced by pepsin digestion essentially
as described earlier (15). Brieﬂy, after incubation of D2B IgG for 3 h
at 37 °C with pepsin in 0.15 M sodium citrate (pH 3.8), digestion was
stopped by adjusting the pH of the solution to pH7.0 with 1.0 M
Tris. F(ab′)2 fragments were puriﬁed using a cation exchange
column (Mono-SH/R 5/5, Pharmacia, Uppsala, Sweden) that was
eluted with 40mM sodium acetate buffer (pH6.0) with a 0–400mM
lithium chloride gradient. The F(ab′)2 fragment containing fractions
were identiﬁed by sodium dodecyl sulfatepolyacrylamide gel
electrophoresis and pooled.
Fab fragments were generated by papain digestion (6h at 37 °C)
of D2B IgG using papain immobilized on agarose resin according
to the protocol of the manufacturer (Thermo Scientiﬁc, Pierce
Fab Preparation Kit) followed by puriﬁcation using protein A
afﬁnity chromatography and dialysis.
2.2. Cell culture
The human prostate cancer cell lines PC3 (PSMA) and LNCaP
(PSMA+) derived from a bone metastasis and a supraclavicular
lymph node, respectively, were used. Both cell lines were
obtained from the ATCC and grown in RPMI 1640 medium,
supplemented with 10% fetal calf serum (Life Technologies,
Bleiswijk, The Netherlands) and glutamine 2 mM.
2.3. Mouse models
Male BALB/c nude mice (Janvier, Le Genest Saint Isle, France),
8–9weeks old, housed in ﬁlter-topped cages (ﬁve mice per
cage) under nonsterile standard conditions with free access
to standard animal chow and water, were adapted to laboratory
conditions for 1week before experimental use. Mice were sub-
cutaneously inoculated with 3×106 LNCaP cells (right ﬂank)
suspended in 200μl of 33% complete RPMI 1640 medium with
67%Matrigel (BD Biosciences) and with 3×106 PC3 cells (left ﬂank)
suspended in 200μl of 67% complete RPMI 1640 medium with
33%Matrigel. LNCaP cells were inoculated 7days prior to PC3 cells.
LNCaP and PC3 tumors grew to approximately 0.1 g in 14 and
7days after tumor cell inoculation, respectively.
All experiments have been approved by the institutional Animal
Welfare Committee of the Radboud University Medical Center and
were conducted in accordance with the principles set forth by
the Revised Dutch Act on Animal Experimentation.
2.4. Radiolabeling of D2B
The murine mAb D2B IgG and all fragments were conjugated
with p-isothiocyanatobenzyl-diethylenetriaminepentaacetic acid
(ITC-DTPA; Macrocyclics) in 0.1 M NaHCO3, pH 9.5, with a 10-fold
molar excess of ITC-DTPA [2.5mg D2B IgG with 110μg ITC-DTPA,
4.5mg F(ab′)2 with 250μg ITC-DTPA and 0.75mg Fab with
100μg ITC-DTPA]. After incubation for 1 h at room temperature,
the reaction mixture was dialyzed for 3 days in a Slide-A-Lyzer
(20 kDa cutoff, Pierce) against 0.25 M NH4Ac, pH 5.4.
For biodistribution studies, D2B IgG-DTPA (28μg), F(ab′)2-DTPA
(22μg), Fab-DTPA (20μg) and capromab pendetide (30μg) were
radiolabeled with 3.7MBq 111In-chloride (Covidien, Petten, Nether-
lands) in 0.1M MES buffer pH5.4 (three times the volume of 111In-
chloride) and incubated during 30min at room temperature under
metal-free conditions. For SPECT/CT studies, D2B IgG-DTPA (20μg),
F(ab′)2-DTPA (25μg), Fab-DTPA (25μg) and capromab pendetide-
DTPA (30μg) were labeled with 111In in 0.1 M MES buffer pH5.4 at
speciﬁc activities of 2.57GBq/nmol (D2B IgG), 982.3MBq/nmol (F
(ab′)2), 232.4MBq/nmol (Fab), and 56MBq/nmol (capromab
pendetide). Volumes of the radiolabeling reaction were 1.3ml
(D2B IgG), 1.5ml [F(ab′)2], 2.0ml (Fab) and 1.5ml (capromab
pendetide). Following incubation, 50mM EDTAwas added to the ﬁ-
nal concentration of 5mM to chelate unincorporated 111In.
The labeling efﬁciency was determined by instant thin-layer
chromatography on silicagel strips (ITLC-SG; Gelman Sciences,
Ann Arbor, MI, USA) using 15mM citrate buffer, pH 6.0, as the mo-
bile phase. The radiochemical purity of the preparations that
were used in the biodistribution experiments was 95, 58, 90
and 95%, for 111In-labeled D2B IgG-DTPA, F(ab′)2-DTPA, Fab-
DTPA and capromab-DTPA, respectively. For SPECT-imaging, it
was 70, 79, 97 and 95%, respectively.
111In-labeled D2B IgG-DTPA, F(ab′)2-DTPA, Fab-DTPA, and
capromab-DTPA were puriﬁed by gel ﬁltration on a PD-10
column. The radiochemical purity was determined by ITLC and
exceeded 97% for all preparations used in the studies.
2.5. Immunoreactivity
The immunoreactive fractions of the radiolabeled antibody/
fragment preparations were determined using freshly trypsinized
LNCaP cells, essentially as described by Lindmo et al. (16,17). The
activity in the vials and in the cell pellet after washing with 500μl
binding buffer was determined in the gamma counter (Wizard 3′′
1480, LKB-Wallac, Oy, Finland) after incubation of 1 h at 37 °C.
Immunoreactive fractions of all radiolabeled preparations used in
the experiments exceeded 80%. For 111In-capromab pendetide,
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the assay was carried out on live and permeabilized LNCaP cells
using the Fix & Perm Cell Fixation and Permeabilization Kit
(Invitrogen) to permeabilize the cells.
2.6. Competitive binding assay
The IC50 of D2B IgG, F(ab′)2 and Fab fragments was determined
in a competitive binding assay on LNCaP cells using 111In-labeled
D2B as a tracer. LNCaP cells were grown to conﬂuency in six-well
plates, and incubated on ice for 2 h in 1ml of binding buffer with
1.85 kBq of 111In-labeled D2B IgG and increasing concentrations
(0.005–300 nM) of unlabeled D2B IgG, F(ab′)2 and Fab fragments.
Cells were washed with binding buffer after incubation and the
cell-associated activity was measured in a gamma counter. IC50
values were calculated using GraphPad Prism software, version
5.03 (GraphPad, La Jolla, CA, USA).
2.7. Flow cytometric analysis
For cell surface staining, LNCaP cells were incubated with either
the mAbs D2B IgG, capromab pendetide or an isotype control
murine IgG (Jackson ImmunoResearch) in phosphate-buffered
saline (PBS) with 2% of bovine serum albumin (BSA) and 2%
human serum (HS) for 30min on ice. Part of the cells were ﬁxed
in 2% paraformaldehyde and incubated in PBS, 2% HS and 0.1%
saponin to permeabilize the cells. After the incubation, samples
were washed three times in PBS or PBS and 0.1% saponin and
incubated for 20min on ice with the secondary anti-mouse-alexa
488 antibody for staining. Cells were analyzed in a FACSCalibur
ﬂow cytometer equipped with CellQuest software (BD Biosciences).
2.8. Biodistribution studies
The effect of mAb protein dose on the biodistribution of 111In-D2B
in nudemice with subcutaneous LNCaP tumors was determined in
groups of ﬁve mice that received different protein doses of 111In-
D2B IgG (0.1, 1, 3, 10, 30 or 100μg of D2B IgG per mouse,
0.4MBq). Mice were euthanized with CO2/O2 asphyxiation 3days
after injection of 111In-D2B IgG. Blood samples were obtained by
heart puncture and tissues (LNCaP tumor, muscle, lung, spleen,
kidney, liver, pancreas, stomach, duodenum and prostate) were
dissected, weighed, and the radioactivity was measured in a
gamma counter. For calculation of the uptake of radioactivity in
each tissue as a fraction of the injected dose, an aliquot of the in-
jection dose was counted simultaneously.
In a subsequent study, 111In-D2B IgG (0.4MBq, 3.0μg/mouse),
111In-F(ab′)2 (0.4MBq, 2.2μg/mouse),
111In-Fab fragments
(0.4MBq, 1μg/mouse) or 111In-capromab pendetide (0.4MBq,
5μg/mouse) was injected i.v. into groups of ﬁve mice with sub-
cutaneous PC3 tumors (left ﬂank) and LNCaP tumors (right ﬂank).
In addition, for Fab and F(ab′)2, ﬁve mice per antibody format
received an excess of unlabeled D2B IgG (300μg/mouse) two
days before injection of the 111In-labeled fragments. For D2B
IgG and capromab pendetide, the excess of unlabeled D2B IgG
or capromab was injected on the same day as the 111In-labeled
antibodies. Mice were euthanized by CO2/O2 asphyxiation and
the biodistribution of 111In-D2B IgG was determined at 1, 2, 4,
24, 72 and 168 h after injection. Because of their more rapid
clearance, biodistribution of the 111In-F(ab′)2 and
111In-Fab frag-
ments was determined at 1, 2, 4 and 24 h after injection. Activity
concentrations in the tissues (% ID/g) were determined as de-
scribed above.
2.9. MicroSPECT/CT imaging
Four groups of ﬁve mice with subcutaneous LNCaP (right ﬂank)
and PC3 (left ﬂank) tumors were injected with 37MBq of
111In-D2B IgG (3.0 μg/mouse), 111In-F(ab′)2 (1.5 μg/mouse),
111In-Fab (1μg/mouse) and 111In-capromabpendetide (5μg/mouse),
Figure 1. Flow cytometric (FACS) analysis of D2B IgG and capromab pendetide on live (black peaks) and saponin-permeabilized (gray lines) LNCaP
cells showing intracellular binding of capromab pendetide.
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respectively. The mice that received 111In-labeled D2B IgG and
capromab pendetide, SPECT/CT scans were imaged 0, 1, 3 and
7 days after injection using a small animal SPECT/CT scanner
(U-SPECT II, MILabs, Utrecht, Netherlands; acquisition time
30–90min, depending on the time point) with a 1.0mm diameter
pinhole collimator tube. Mice injected with 111In-F(ab′)2 and
111In-Fab fragments underwent SPECT/CT at 0, 1 and 2days
after injection. For Fab and F(ab′)2, two additional mice were
injected with an excess of unlabeled D2B IgG 2days before
injection of the 111In-labeled antibody fragments. For D2B IgG,
the excess of unlabeled antibody formats was coadministered
on the same day as 111In-D2B.
After the last scan, mice were euthanized and biodistribution
of the 111In-D2B, 111In-F(ab′)2,
111In-Fab or 111In-capromab pen-
detide was determined as described above. Scans were recons-
tructed with MILabs reconstruction software (MILabs, Utrecht,
Netherlands), which uses an ordered-subset expectation maxi-
malization algorithm.
2.10. Statistical analysis
Statistical analyses were performed with Graphpad Prism,
version 5.03. Results are presented as mean ± standard devia-
tion (SD). Differences in tumor uptake of the antibody formats
were tested for signiﬁcance using the two-tailed t-test. A
p-value below 0.05 was considered signiﬁcant.
3. RESULTS
3.1. In vitro characterization
Flow cytometric analysis (FACS) with live and permeabilized
LNCaP cells revealed high binding of D2B IgG to live
(95.9 ± 2.2%) as well as to permeabilized cells (96.9 ± 1.7%). In
contrast, for capromab pendetide, binding to live cells was low
(7.6 ± 0.7%), while binding to permeabilized cells was high
(96.1 ± 1.1%), showing that D2B recognizes an epitope on the
cell surface, while capromab is directed against an intracellular
epitope (Fig. 1).
For 111In-D2B IgG the immunoreactive fraction on live LNCaP cells
was 84.1%, and the immunoreactive fractions of 111In-capromab
pendetide on permeabilized LNCaP cells were 93.6%, indicating that
the immunoreactivity of both antibodies was preserved during the
labeling procedure.
The IC50 of D2B IgG and F(ab′)2 fragments was 3.7 nM
(95% conﬁdence interval, CI: 2.8–4.8nM) and 1.9nM (CI 1.6–2.3nM),
respectively, whereas it was slightly lower for Fab fragments
(8.9 nM; CI 7.1–11.0 nM Fig. 2), which could be due to the
monovalency of Fab fragments.
Figure 2. Competitive binding curves of IC50 determination of D2B IgG,
F(ab′)2 and Fab fragments on prostate-speciﬁc membrane antigen
(PSMA)-positive LNCaP cells.
Figure 3. Biodistribution results of the dose escalation of 111In-D2B in mice (n=5) with subcutaneous LNCaP xenografts. Data are presented as mean±SD.
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3.2. Biodistribution studies
In the dose escalation study an inverse correlation between
the D2B antibody protein dose and the uptake in the LNCaP
tumor was observed: LNCaP tumor uptake of 111In-D2B IgG
decreased from 52 ± 5% ID/g at 0.1 μg/mouse to 26 ± 1.5%
ID/g at 100 μg/mouse. Highest tumor uptake (54 ± 4% ID/g)
Figure 4. Ex vivo biodistribution of nude mice bearing subcutaneous PSMA-negative PC3 and PSMA-positive LNCaP xenografts at several time points after
intravenous injection of (a) 111In-D2B IgG, (b) 111In-F(ab′)2, (c)
111In-Fab fragments and (d) 111In-capromab pendetide. Data are presented as mean±SD.
S. LÜTJE ET AL.
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was observed at D2B doses≤3μg/mouse at 3days p.i. (Fig. 3). At
that time point, tumor-to-blood ratios ranged from 4.3 (at 0.1μg/
mouse) to 1.8 (at 100μg/mouse). Tumor weight was 0.04g±0.02g
(D2B IgG group), 0.08g±0.03g (F(ab′)2 group), 0.07g±0.02g
(Fab group) and 0.10g±0.02g (capromab group).
For biodistribution studies, 111In-D2B IgG (0.4MBq, 3.0μg/mouse),
111In-F(ab′)2 (0.4MBq, 2.2μg/mouse),
111In-Fab fragments (0.4MBq,
1μg/mouse) or 111In-capromab pendetide (0.4MBq, 5μg/mouse)
was injected inravenously. All three 111In-labeled D2B antibody
formats speciﬁcally accumulated in the s.c. PSMA+ LNCaP tumors
(right ﬂank), while uptake in PSMA PC3 xenografts (left ﬂank)
remained low. LNCaP tumor uptake increased for 111In-D2B IgG
from 2.2 ± 2.0% ID/g at 1 h p.i. to 94.8± 19.2% ID/g at 168 h after
injection, the latter representing the highest tumor uptake
observed in these studies (Fig. 4). For 111In-F(ab′)2 and
111In-
Fab, LNCaP tumor uptake ranged from 1.6± 0.6 and 4.1± 0.9%
ID/g at 1 h p.i. to 12.1± 3.0 and 15.1± 2.9% ID/g at 24 h after
injection, respectively. For 111In-labeled capromab pendetide,
LNCaP tumor uptake ranged from 0.7 ± 0.4% ID/g at 1 h p.i. to
16.7± 2.2% ID/g at 168 h after injection, reaching a maximum
of 17.4± 2.8% ID/g 3days after injection.
Tumor uptake of the three D2B formats could be blocked by
coinjection of an excess of unlabeled mAb. The uptake of 111In-
D2B IgG decreased from 60.9 ± 11.0 to 12.3 ± 7.1% ID/g at 72 h
p.i.. The LNCaP uptake of 111In-F(ab′)2, decreased from 4.8 ± 2.1
%ID/g to 3.5 ± 1.8% ID/g (4 h p.i.), while the LNCaP uptake of
111In-Fab decreased from 8.5 ± 2.4% ID/g to 3.9 ± 0.4% ID/g, re-
spectively at 4 h p.i.. Maximum uptake in the PSMA-negative
PC3 tumor was 9.1 ± 1.3% (24 h p.i.), 6.8 ± 1.3% (4 h p.i.) and
6.3 ± 1.1% ID/g (2 h p.i.) for 111In-labeled IgG, F(ab′)2 and Fab, fur-
ther conﬁrming the speciﬁc uptake of the D2B antibody formats
in the PSMA+ tumor.
Maximum LNCaP tumor-to-blood ratio for 111In-D2B IgG was
13.0 ± 2.3 (168 h p.i.). For D2B Fab and F(ab′)2 fragments, high
tumor-to-blood ratios were reached faster compared with tumor-
to-blood ratios of D2B IgG, with a maximum of 23.0± 4.0 and
6.2± 0.7, respectively, 24h after injection (Table 1). The highest
LNCaP tumor-to-blood ratio of 111In-labeled capromab pendetide
was 4.5± 0.6, reached 7days after injection. LNCaP tumor-to-
muscle ratio for 111In-D2B IgG (168 h p.i.), 111In-F(ab′)2 (24 h p.i.),
111In-Fab (24h p.i.) and 111In-capromab pendetide (168h p.i.) were
94.8± 19.2, 12.1± 3.0, 15.1 ± 2.9, and 16.7± 2.2, respectively.
3.3. MicroSPECT/CT Imaging
Coronal sections of SPECT/CT images of all 111In-labeled anti-
body formats through the center of subcutaneous PSMA+ LNCaP
and PSMA PC3 tumors are displayed in Fig. 5. At 24 h p.i., LNCaP
tumors were clearly visualized with all formats. The optimal time
point for imaging with 111In-D2B IgG and 111In-capromab
pendetide was 168 h p.i. and for 111In-F(ab′)2 and
111In-Fab this
was 48 h p.i. Tumor uptake was speciﬁc for 111In-D2B IgG,
111In-F(ab′)2 and
111In-Fab since tumor uptake was markedly
lower in mice coinjected with an excess of unlabeled D2B
IgG (Fig. 5). Uptake in the PSMA PC3 tumors remained low
for all antibody formats at all time points.
For D2B F(ab′)2 and Fab fragments, high accumulation of
111In in
the kidneys, especially the renal cortex, was observed, indicating
that these antibody preparations were cleared via the kidneys ap-
parently with tubular reabsorption of the 111In-labeled metabolites.
4. DISCUSSION
In the present study, the in vivo tumor targeting characteristics of
111In-D2B IgG, 111In-F(ab′)2, and
111In-Fab fragments for targeting
of prostate cancer were examined in mice with human prostate
cancer xenografts using 111In-labeled capromab pendetide as
a reference.
Since intact antibodies clear slowly from the circulation and
maximum tumor uptake is reached at 3–7 days after injection,
we included F(ab′)2 and Fab fragments of D2B in our studies to
investigate whether further improvements in prostate cancer
targeting would be possible by using D2B antibody fragments.
The slow accumulation of intact antibodies has been attributed
Table 1. Ex vivo biodistribution (tissue uptake % ID/g) and LNCaP tumor-to-organ ratios of 111In-capromab pendetide, 111In-D2B
IgG, 111In-F(ab′)2 and
111In-Fab fragments in nude mice with subcutaneous prostate-speciﬁc membrane antigen (PSMA)-negative


































Blood 3.7 ± 0.3 4.5 ± 0.6 7.3 ± 0.7 13.0 ± 2.3 2.0 ± 0.3 6.2 ± 0.7 0.7 ± 0.0 23.1 ± 4.0
Muscle 0.5 ± 0.1 31.9 ± 6.5 0.9 ± 0.2 110.4 ± 41.1 0.7 ± 0.2 18.4 ± 3.4 0.5 ± 0.4 38.2 ± 19.8
Lung 3.0 ± 0.4 5.5 ± 0.7 4.3 ± 0.8 22.8 ± 6.3 2.1 ± 0.1 5.7 ± 1.2 0.9 ± 0.1 20.0 ± 4.2
Spleen 5.3 ± 0.4 3.5 ± 0.6 3.1 ± 0.13 30.9 ± 6.4 5.5 ± 0.7 2.8 ± 0.4 1.1 ± 0.1 13.2 ± 2.4
Pancreas 1.1 ± 0.1 14.9 ± 1.0 1.0 ± 0.2 98.9 ± 18.6 0.9 ± 0.0 14.1 ± 3.4 0.3 ± 0.0 45.8 ± 12.1
Kidney 9.0 ± 0.6 1.9 ± 0.3 2.7 ± 0.4 35.5 ± 7.5 57.8 ± 6.4 0.2 ± 0.0 102.8 ± 8.5 0.2 ± 0.0
Stomach 1.00 ± 0.1 17.6 ± 2.5 0.9 ± 0.2 104.0 ± 31.0 1.1 ± 0.1 11.4 ± 1.5 0.4 ± 0.0 35.5 ± 8.8
Duodenum 1.4 ± 0.2 11.9 ± 2.4 1.5 ± 0.1 64.3 ± 14.3 1.4 ± 0.2 8.5 ± 2.5 0.4 ± 0.0 37.3 ± 9.7
Liver 5.5 ± 0.7 3.1 ± 0.7 3.4 ± 0.3 28.2 ± 4.6 7.3 ± 0.4 1.7 ± 0.3 1.4 ± 0.1 10.8 ± 2.3
Prostate 1.8 ± 0.2 9.5 ± 1.8 1.7 ± 0.5 59.2 ± 14.4 1.6 ± 0.3 8.0 ± 3.2 0.6 ± 0.1 25.7 ± 5.8
PC3 tumor 7.1 ± 1.2 2.4 ± 0.4 6.7 ± 0.9 14.0 ± 1.2 6.5 ± 1.0 1.9 ± 0.2 2.2 ± 0.4 7.1 ± 2.0
LNCaP
tumor
16.7 ± 2.2 94.8 ± 19.2 12.1 ± 3.0 15.1 ± 2.9
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Figure 5. Representative SPECT/CT images of mice bearing subcutaneous PSMA-negative PC3 (left ﬂank, green arrows) and PSMA-positive
LNCaP (right ﬂank, blue arrows) prostate cancer xenografts at several time points after intravenous injection of 111In-D2B IgG, 111In-F(ab′)2,
111In-Fab fragments and 111In-capromab pendetide.
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to the slow blood clearance of intact IgG in combination with the
presence of various physiological barriers between the circula-
tion and the tumor cell surface (18). It has been pointed out that
the vascular endothelium, the relatively large transport distances
in the tissue and the enhanced interstitial ﬂuid pressure in the
tumor tissue hamper the penetration of antibodies into the tu-
mor tissue to bind to their target antigen. Antibody fragments
such as F(ab′)2 and Fab fragments are cleared more rapidly from
the blood, mainly because they lack the CH2 domain, which
causes IgG molecules to recycle into the bloodstream via the
FcRn receptor (19). On the other hand, the sustained blood levels
of intact IgG molecules are the driving force for their accumula-
tion in tumors. Therefore, the uptake of antibody fragments in
tumors is lower than that of intact IgGs, as was also observed
in the present study. Because the diffusion rate of a molecule is
linearly correlated to its molecular size (20), antibody fragments
diffuse more rapidly in the interstitial ﬂuid. Owing to the more
rapid blood clearance, higher tumor-to-blood ratios are
obtained. With the antibody fragments, tumors can be visualized
more rapidly: optimal images can be acquired within 24 h p.i.,
whereas intact IgG can be used when high concentrations of
the antibody in the tumor are required (e.g. in therapeutic appli-
cations when high payloads of toxic agents should be targeted
to the tumor).
Here, we observed that the tumor uptake of 111In-D2B IgG was
higher than that of 111In-F(ab′)2 and
111In-Fab at all time points,
even as early as 24 h after injection. However, at early time points
after injection, tumor–nontumor ratios of 111In-F(ab′)2 and
111In-Fab were higher than those of 111In-D2B IgG, indicating
that the antibody fragments are preferred for imaging pur-
poses. For the evaluation of response to therapy, when
imaging early after tracer injection is required, and to deter-
mine tracer uptake before and shortly after intervention,
antibody fragments should be used.
In contrast to 111In-D2B IgG, the renal clearance of 111In-F(ab′)2
and 111In-Fab resulted in high accumulation in the kidneys, most
likely owing to tubular reabsorption after glomerular ﬁltration of
these antibody preparations. Usually, the threshold for glomeru-
lar ﬁltration is approximately 60 kDa, suggesting that the anti-
body fragments are catabolized into smaller molecules in the
kidneys (21). Renal clearance and accumulation of F(ab′)2 and
Fab fragments might be a disadvantage, since it might interfere
with visualization of malignant tissue located in the vicinity of
the kidneys and the urinary bladder.
For the characterization of the tumor targeting capacities of 111In-
D2B IgG, 111In-F(ab′)2 and
111In-Fab fragments, 111In-labeled
capromab pendetide was used as a reference in this study. Since
capromab pendetide targets an intracellular epitope of PSMA,
internalization or uptake into the cell by another process is
required to bind to PSMA. It has been postulated that
capromab pendetide may only bind dying or necrotic cells with
cellular membranes that are permeable for IgG (22). Therefore,
111In-capromab pendetide has low sensitivity for viable tumor
lesions, which makes it a suboptimal agent for diagnostic imaging
of prostate cancer. Still, speciﬁc tumor targeting of the PSMA+
LNCaP tumors was observed with 111In-labeled capromab pen-
detide, although at a much lower level than 111In-D2B IgG.
Overall, the new mAb D2B IgG has excellent in vivo tumor
targeting characteristics. In addition, 111In-F(ab′)2 and
111In-Fab
fragments of D2B IgG are feasible for SPECT or PET imaging of
PSMA-expressing prostate cancer. The preparations based on
antibody fragments allow imaging at early time points after
injection, while the preparation based on intact D2B IgG has a
higher absolute uptake in the tumor.
5. CONCLUSION
111In-labeled D2B IgG can be used for imaging of PSMA-expressing
cancer, as shown in mice with s.c. PSMA-expressing tumors. The
xenografts were clearly visualized in SPECT/CT with speciﬁc differ-
entiation between PSMA and PSMA+ tumors. Compared with
111In-capromab pendetide, higher tumor-to-blood ratios were
obtained. Owing to renal accumulation of F(ab′)2 and Fab frag-
ments, visualization of malignant tissue located in the vicinity of
the kidneys might be hampered. However, especially in settings
where multiple images within a short time interval are required,
111In-D2B F(ab′)2 and Fab fragments can be used.
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